Skip to main content

25 MARCH, 2005

NucliSens® miniMAG™, bioMérieux’s next generation nucleic acid extraction platform is now available as CE-IVD approved platform

Marcy l'Etoile, France - March 25, 2005. bioMérieux announces the introduction of the NucliSens miniMAG and NucliSens Magnetic Extraction Reagents as CE-IVD marked products. A major actor in the field of in vitro diagnostics (IVD), bioMérieux thereby reinforces its commitment to quality and fulfilment of the most stringent regulatory requirements.

"The CE-IVD marking of bioMérieux's state-of-the-art magnetic extraction platform, NucliSens miniMAG, is an important step towards providing our customers with molecular diagnostic products that are fully approved to be used for in vitro diagnostic purposes" says Jean-Marc Chermette, Vice-President for Molecular Diagnostics at bioMérieux.

NucliSens miniMAG is a highly flexible platform that works with a universal procedure, capable of effectively extracting both RNA and DNA for a broad number of sample types*. Since its introduction last year, extensive feedback has been received from world-wide users reporting the very high quality of the extracts.

bioMérieux will, of course, continue its efforts to further enhance the quality of its products to meet the highest expectations of the key actors in the molecular diagnostics field. “Choosing the NucliSens miniMAG platform in sample preparation is definitely the solution of simplicity and quality !" adds Jean-Marc Chermette.

* Today, optimized protocols are available for the following sample types: plasma, serum, whole blood, stool, sputum, CSF.